Fundraising Fox
Foster City · Seed–Series A · 40 people tracked
Also known as IIF MANAGEMENT COMPANY, LLC
Find your way into Illumina Ventures
Sign up to see every warm intro you have to Illumina Ventures
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Illumina Ventures team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
Illumina Ventures positions itself as a leader in genomics and precision health investing. The firm concentrates on building the broader ecosystem around these fields and translating capital into innovation, with the stated goal of accelerating positive impact on human health.
Source: firm website, verified Oct 13, 2026.
Team · 40 people
from the firm's website & curated & public directories
Nick Naclerio's background spans USAF, DARPA, semiconductors and founding Motorola Life Sciences; he has deployed $500M+ into genomics companies that change standard of care and tackle climate via agriculture.
Founding Partner of Illumina Ventures focused on companies at the intersection of technology and human health. Previously SVP of Corporate & Venture Development at Illumina Inc., co-founder and Executive Chairman of Quanterix, and CEO of ParAllele BioScience, with earlier venture experience at Motorola Life Sciences and leadership roles at DARPA.
Abhijit Ron Mazumder, nearly 30 years in genomics and biomarkers with senior oncology biomarker roles at Genentech, built a hybrid platform supplying in‑kind sequencing and up‑to‑two‑year monthly founder sessions.
Ron has nearly 30 years of experience in biomarkers, technologies, and computational approaches for pharmaceutical and diagnostics programs. He previously worked at Johnson & Johnson, Merck, and was VP and global head of Oncology Biomarker Development and Companion Diagnostics at Genentech.
Mara Aspinall—operator leader at Genzyme and Ventana/Roche and a widely cited COVID‑19 testing authority who built TestingCommons—identifies diagnostics companies able to scale to population and policy levels.
Wouter Meuleman is a venture capital partner and founding member with electrochemistry training and operator-level genomics experience—building Illumina sequencing platforms, first employee at Oxamer, and collaborating with Sir Edwin Southern.
Ron Mazumder is a Partner at Illumina Ventures with 30 years of experience in biotechnology, diagnostics, and precision medicine. His background spans biomarker development, companion diagnostics, translational medicine, and drug development strategy across biotech and pharmaceutical organizations, including work on clinical development and regulatory submissions. He focuses on building AI-enabled therapeutics, diagnostics, and tools companies.
An electrochemist by training with over 20 years in life sciences tools and genomics, Wouter was part of the founding team at Illumina Ventures. He previously served as director of Corporate Development at Illumina, leading investments and holding senior R&D and product development roles, and earlier worked with Prof. Sir Edwin Southern at Oxford spin-out Oxamer.
Charles White joined Illumina Ventures from Putnam Associates, where he advised biotech and pharmaceutical companies on strategy, competitive positioning, market research, forecasting, and acquisitions. He holds a Ph.D. from UCSF, where he researched the biochemical mechanisms of age-related regenerative decline in the brain, and a dual B.S. in Biotechnology and Biochemistry from Worcester Polytechnic Institute.
A life sciences technologist and serial entrepreneur, Yuling is founder, chairman and CEO of Alamar Biosciences and inventor of the RNAscope molecular detection technology. He previously founded and led Advanced Cell Diagnostics (acquired by Bio-Techne for $325M in 2016), co-founded Panomics (acquired by Affymetrix in 2008), and was an early senior scientist at Exelixis.
Tom Willis is a genomics entrepreneur who founded and exited two startups: ParAllele BioScience (acquired by Affymetrix in 2005) and Sequenta (merged with Adaptive Biotechnologies in 2015). He earlier led technology development at the Stanford Genome Technology Center and became CEO of Arima Genomics in June 2025.
A biotechnology investor and industry veteran, Bill Rastetter served on Illumina's board for 17 years, including a decade as chairman, and holds board roles at companies including GRAIL, Neurocrine Biosciences, and Fate Therapeutics. He co-founded and chaired Receptos (sold to Celgene in 2015), led the merger forming Biogen Idec, co-invented the cancer therapy Rituxan at Idec Pharmaceuticals, and holds a PhD in Chemistry from Harvard.
David R. Walt is the Hansjörg Wyss Professor of Bioinspired Engineering and a professor of Pathology at Harvard Medical School and Brigham and Women's Hospital, and a core faculty member of the Wyss Institute. He is the scientific founder of Illumina and Quanterix and co-founded several life science startups, pioneering microwell arrays for single-molecule detection.
Donal Delaney is Illumina Ventures' CFO with a background spanning venture capital, venture debt, public accounting and financial systems. He previously served as CFO at Pinnacle Ventures and corporate controller at SVB Financial Group, and worked as an auditor at KPMG and Ernst & Young.
Pharmacologist, innovator, and entrepreneur focused on translating early-stage innovations into clinical development programs. He founded Sigmoid Pharma, where as CEO he raised over €90M in equity and led its drug delivery technology development, and holds a PhD in Cancer Research and an MBA from Cornell.
Jerry Steiner focuses on using genomics to make agriculture more sustainable. He is executive chairman of Illumina Ventures portfolio company Pluton Biosciences, co-founded and led CoverCress (sold in 2022), and previously held senior sustainability, strategy and general management roles at Monsanto, and was part of the leadership team at Celera Genomics.
Jessica Wong oversees finance, accounting, and reporting for Illumina Ventures' funds, GPs, management company, and Labs entities, bringing over 15 years of PE/VC accounting and tax experience. She previously worked at Deloitte & Touche, Silver Lake Partners, CM Capital Advisor, and Pinnacle Ventures.
A physician-scientist and entrepreneur who co-founded Sequenta (acquired by Adaptive Biotechnologies in 2015) and ParAllele Biosciences (acquired by Affymetrix in 2005), later serving as VP of Research and Oncology Technology at Affymetrix. He holds a Ph.D. in Human Genetics and an MD from UCSF, with 60 peer-reviewed publications and 40 US patents.
A scientific entrepreneur with 25 years in therapeutics, diagnostics and omics tools, combining AI, machine learning, computational biology and genomics expertise. Previously CTO at Encoded Therapeutics and SVP of R&D at Adaptive Technologies, with prior roles at Sequenta, Affymetrix and ParAllele Biosciences. Holds a PhD in Particle Astrophysics from Oxford and an MSc in Computer Science from Imperial College London.
Natalie provides executive support and co-manages daily office operations at Illumina Ventures. She previously worked in customer service and administrative roles at Bank of America and holds an associate's degree in Business Administration and Software Technology from Heald College in California.
Ronan is a CEO and commercial leader with over two decades of experience building and selling companies, including Beverly Records Management (sold to Iron Mountain) and Engage Technologies (sold to Northgate Plc). He has focused on commercializing life sciences innovations, co-founding and exiting ClearSight Innovations, and currently leads spin-out Pharma Latch, while mentoring life sciences companies for organizations like Enterprise Ireland. He holds a bachelor's degree in Economics and Politics and an MBA from University College Dublin.
Rose Lai serves as senior executive assistant to Illumina Ventures founder Nick Naclerio and as the firm's co-office manager. She previously held executive assistant and research assistant roles at Piper Jaffray, Seven Hills Group, and GCA Savvian.
A physician-scientist with expertise in molecular diagnostics, genetics, oncology and infectious diseases, Tim previously directed the FDA's Office of In Vitro Diagnostics and held leadership roles at Invivoscribe and Quidel Corporation, as well as spending 21 years on the Duke University School of Medicine faculty. He holds an MD and PhD from Duke and a BA in Chemistry from Grinnell College.
Yogesh provides operational and scientific support to startups at Illumina Ventures Labs UK, drawing on over 14 years of experience in molecular biology and genomics. He joined in 2025 after serving as a Senior Scientist at BenevolentAI and holding scientific roles at Quell Therapeutics, NHS Genomics Core, and King's College London.
William Byrne is a Senior Associate based in Ireland who previously served as head of Biotechnology at NEOM in Saudi Arabia, where he set scientific focus areas and built biotech industry enablers. He earlier worked in healthcare and life sciences strategy consulting and at a bacterial gene therapy biotech startup.
A creative professional with over a decade of experience as an art director, graphic designer, marketer, animator, and illustrator, holding a BFA in Animation from the Art Institute of Boston.
Analyst studying Finance & Entrepreneurship, class of 2028.
Founder mafia
7 people who came through Illumina Ventures went on to found or lead other companies.
What they invest in
from 51 of 58 portfolio companiesBiotech ×47Healthtech ×19AI & Machine Learning ×17Deep Tech ×17Medical Devices ×16Digital Health ×12Hardware ×3AgTech ×2
HQs:United States×38United Kingdom×2France×1Ireland×1Sweden×1
Who they back
founder profiles across 34 portfolio companiesFounding team size:solo founder×122 founders×93 founders×84+ founders×5
Where their founders studiedfrom 36 founders with education data
Case Western Reserve University ×2Harvard Business School ×2Sharif University of Technology ×2University of Oxford ×2University of Science and Technology of China ×2
What their founders studiedfrom 42 founders with field-of-study data
Life Sciences ×24Engineering ×6Mathematics & Statistics ×5Business & Management ×4Chemistry ×4Computer Science ×3Medicine ×3Physics ×3
Where their founders worked beforefrom 40 founders with career history
Massachusetts Institute of Technology ×5Harvard Medical School ×4Brigham and Women's Hospital ×3UC Berkeley ×310x Genomics ×2Broad Institute of MIT and Harvard ×2Dana-Farber Cancer Institute ×2Harvard University ×2
29 founders hold a PhD · 3 hold an MBA (of 42 with degree data)
Investments · 58 tracked
founders shown can be your intro pathBy year:2026 · 42025 · 22024 · 12023 · 12022 · 42021 · 72020 · 32019 · 22018 · 32017 · 330 dated
Castle Biosciences develops genomic diagnostic tests that use a patient's molecular biology to inform disease management and treatment decisions.
BiotechDigital HealthHealthtechFriendswood, US
Derek J. Maetzold(President, CEO and Director)inFrank Stokes(Chief Financial Officer)inKristen Oelschlager(Chief Operating Officer)inToby Juvenal(Chief Commercial Officer)inHillary Caruso(Chief of Staff)inTobin W. Juvenal(Chief Commercial Officer)
Co-investorsBioBritMountain Group Capital
Pattern develops rapid antibiotic susceptibility and infection diagnostics using single-cell microbiology, which reads the metabolic patterns of individual bacterial cells to deliver ID/AST results in hours without culture steps.
BiotechHealthtechMedical DevicesAustin, US
Nick Arab(Founder & CTO)Ross Johnson(Co-founder & Chief Engineer)inCarey-Ann Burnham(Chief Executive Officer)inTravis Davies(SVP, Operations)inKyle Fieleke(SVP, Corporate Development & Finance)inDavid Bussian(SVP, Clinical, Regulatory & Assay Development)in
Co-investorsAMR Action FundIllumina Innovation
Pluton is developing a sun-powered, soil-surface biological nutrient system that uses photosynthetic microbial consortia to fix atmospheric nitrogen, improve phosphorus availability, and add carbon to soil for crop growers.
AgTechBiotechClimate TechSt. Louis, US
Barry Goldman(Co-founder)inElizabeth Gallegos(Chief Executive Officer)inJerry Steiner(Executive Chair)inCharlie Walch(Executive Officer, Director)inGlendon Schuster(Director)
Co-investorsFirst In VenturesRadicle GrowthFall Line CapitalGrantham FoundationRA CapitalThe Yield Lab+3 more
Precede Biosciences develops a blood-based diagnostic platform that profiles gene expression from cell-free DNA to reveal disease biology at the transcriptional level for drug developers and clinical trials.
AI & Machine LearningBiotechDigital HealthBoston, US
Rehan Verjee(Co-Founder, Chief Executive Officer, Board Director)inSylvan Baca(Co-Founder; Assistant Professor of Medicine, Dana-Farber Cancer Institute)inToni Choueiri(Co-Founder; Director, Lank Center for GU Oncology, Dana-Farber Cancer Institute)Matthew Freedman(Co-Founder; Professor of Medicine, Dana-Farber Cancer Institute)
Co-investors5AM VenturesOUP (Osage University Partners)AlexandriaLilly Asia VenturesS28 CapitalUPMC Enterprises
Predicta Biosciences operates a molecular insights platform for blood cancer care, using whole genome sequencing of intact circulating tumor cells from a single blood sample combined with single-cell immune profiling to characterize disease biology and immune response.
BiotechDigital HealthMedical DevicesCambridge, US
Irene Ghobrial(Co-founder)inKenneth Anderson(Co-founder)Gad Getz(Co-founder)Romanos Sklavenitis-Pistofidis(Co-founder)Keith Flaherty(Co-founder)Brian McKernan(CEO)in
Co-investorsThe Engine Ventures
RedShiftBio develops analytical technology that provides real-time measurement of biomolecular structure and concentration, aimed at supporting decisions in biopharmaceutical development and manufacturing.
BiotechDeep TechHardwareBoxborough, US
Thomas O'Lenic(Executive Officer, Director)Eugene Ma(Executive Officer)Charles Marshall(Executive Officer, Director)
BoardFrank Smith(Director)inWilliam Cadogan(Director)Bryson Hollimon(Director)
Co-investorsTechnology Venture Partners
Actym Therapeutics engineers bacteria as a delivery system for therapeutics targeting cancer and fibrotic disease.
BiotechHealthtechBerkeley, US
Christopher D Thanos(Executive Officer, Director, Promoter)Kanad Das(Director)Amit Kumar(Director, Promoter)James Huang(Director)
Adventris is a biotechnology company developing cancer immunotherapy treatments.
BiotechHealthtechBaltimore, US
Jen Herbach(Founder)inWilliam Collis(Founder)inMark Yarchoan(Founder)Jenny Lesser Herbach(Founder)in
Co-investorsY CombinatorBlackbird BioventuresFelicis VenturesKhosla VenturesPeak XV PartnersRefactor Capital+1 more
Alamar Biosciences develops NULISA, an ultra-high-sensitivity, high-specificity technology for analyzing hundreds of protein biomarkers from small biofluid samples, building on the team's prior spatial genomics work (RNAscope).
BiotechDeep TechHealthtechFremont, US
Yuling Luo(Co-founder, CEO and Chair)inSteve Chen(Co-founder, COO and Director)inYiyuan Yin(Co-founder, VP of Technology)inTod White(President)inJustin McAnear(CFO)inXiao-Jun Ma(CTO)
Co-investorsQiming Venture PartnersSamsara BioCapital
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersOno Venture Investment, Inc.TCG CrossoverAlly Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
Arima Genomics develops DNA-based cancer diagnostics that combine genomic sequence with 3D genome structural information (via Hi-C sequencing) to detect fusions, rearrangements, ecDNA, and other structural drivers of cancer.
BiotechHealthtechMedical Devices
Sid Selvaraj(Founder & Chief Operating Officer)inTom Willis(Chief Executive Officer)inAnthony Schmitt(Senior Vice President, Science)inErin Davis(Vice President, Marketing)in
Co-investorsBerkeley CatalystPhase Two Ventures
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options.
BiotechDigital Health
Zaneta Odrowaz(Founder)inTao Fu, MBA, M.S.(Founder, Chief Executive Officer, and President)Zaneta Odrowaz, Ph.D.(Chief Business Officer and Co-Founder)Petter Veiby(Chief Scientific Officer and Co-Founder)inHangjun Zhan, Ph.D.(Chief Technology Officer and Co-Founder)
Co-investorsEcoR1 CapitalFrazier Life SciencesNextech InvestSanofi VenturesVida VenturesGoldman Sachs+1 more
Broken String Biosciences develops tools for genome-wide on- and off-target analysis in gene editing, enabling in-house detection and characterization of gene editing-induced DNA breaks.
AI & Machine LearningBiotechDeep Tech
Co-investorsFirst In VenturesHeran PartnersKorysMérieux Equity Partners
Bullseye Biosciences uses in-cell directed evolution to discover functional therapeutic molecules against challenging intracellular targets such as protein–protein interactions and transcriptional regulation.
BiotechDeep Tech
Corey Gray(Co-founder and CEO)inMichael McKeown(Co-founder and Head of Research)in
Co-investorsZAKA VC
BiotechPittsburgh, US
Michael Hoerres(Executive Officer, Director)
BoardJames Peters(Director)Steve Grenfell(Director)Paul Schmitt(Director)Noel Doheny(Director)
Co-investorsBen Franklin Technology Partners of Northeastern PennsylvaniaPittsburgh Life Sciences GreenhouseUPMC Enterprises
CubaseBio develops spatial biology tools that enable three-dimensional analysis of biological samples at scale, for drug discovery and biological research.
BiotechDeep TechStockholm, SE
Paulius Mielinis(Founder)inToon Verheyen(Founder)inXiaoyan Qian(Founder)in
Co-investorsLeksell Social VenturesNordic Science InvestmentsVoima Ventures
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Founder)inPeter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)inSusan Tousi(Chief Executive Officer)in
Co-investorsAV8 VenturesForesite CapitalInitiate Venture PartnersMenlo VenturesMerck Global Health Innovation FundMSD Global Health Innovation Fund+7 more
DNA Script develops enzymatic DNA synthesis technology, producing nucleic acids for research and biotech applications.
BiotechDeep TechHardwareParis, FR
Thomas Ybert(Founder)inXavier Godronin
Co-investorsCatalio Capital Management, LPCoatue ManagementKurma PartnersM VenturesSofinnova PartnersCasdin Capital
Encoded develops gene therapies for neurological disorders through an integrated platform approach.
BiotechSouth San Francisco, US
Stephanie Tagliatela(Founder)inKartik Ramamoorthi, Ph.D.(Co-founder, Chief Executive Officer & Board Member)Kartik Ramamoorthi(Founder)
Co-investorsARCH Venture PartnersBioBritGV (Google Ventures)Menlo VenturesSoftBank Vision FundVenrock+2 more
Develops novel ocular therapies.
BiotechMorrisville, US
Ben Yerxa(Executive Officer)inEric Linsley(Executive Officer)in
BoardEd Mathers(Director)inStephen Bloch(Director)inSeth Rudnick(Director)inNeal Fowler(Director)
Co-investorsCanaan PartnersNew Enterprise Associates (NEA)Pappas Capital+ND CapitalARCH Venture PartnersOMX Ventures
Fluent Bio develops software for analyzing single-cell RNA sequencing data, producing count matrices and diagnostic outputs for researchers using Illumina sequencing libraries.
BiotechDeveloper Tools
Co-investorsCivilization Ventures Management, LlcCota CapitalSamsara BioCapital
Fuze Health operates a unified digital healthcare platform spanning digital pharmacy (FuzeRx), clinical services such as diagnostics, screening and genetics (Fuze Services), and data and technology tools (Fuze Technologies).
AI & Machine LearningDigital HealthHealthtechSaaS
Co-investorsFJ LabsHLM Investment PartnersK2 HealthVenturesOlive Tree CapitalQiming Venture Partners USASoftBank Vision Fund+2 more
Genome Medical provides telehealth-enabled genetic services, including genetic counseling, genetic testing, and clinical trial matching, with a focus on individuals with rare conditions.
BiotechDigital HealthHealthtechSouth San Francisco, US
Lisa Alderson(Executive Officer, Director)inRandal Scott(Director)Jill Davies(Executive Officer, Director)inElizabeth Moreno(Executive Officer)inMark Sylvester(Chief Financial Officer)inAndrew Warner(Vice President, Product)in
Co-investorsAlumni VenturesAvestria VenturesCanaan PartnersDreamers VCEcho Health VenturesGV (Google Ventures)+11 more
Genome Medical provides telehealth-enabled genetic counseling, testing, and clinical trial access for patients with rare diseases.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsBlue Ivy VenturesiSelect FundCanaan PartnersWalden Catalyst
Hepta develops LiquidTransformer, an AI platform for analyzing cell-free DNA fragments in blood to detect chronic disease molecular signals.
AI & Machine LearningBiotechHealthtechSan Francisco, US
Hamed Amini(Founder)inSoheil Damangir(Founder)in
Co-investorsAlumni VenturesAME Cloud VenturesFelicis VenturesSeaX Ventures
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Founder)inFred Manby(Founder)inChao Zhang(Executive Officer)inTabbert Teng(Executive Officer)Neil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)in
Co-investorsAscenta CapitalAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue Management+7 more
Infinity Bio provides immune system analysis through its proprietary MIPSA antibody reactome profiling platform, which identifies the targets of individual immune responses against human viruses, human proteins (autoimmunity), and allergen proteins.
BiotechDeep TechHealthtechBaltimore, US
Benjamin Larman(Executive Officer, Director)inJoy M Nassif(Executive Officer, Director)in
BoardMatthew Hellauer(Director)Herman Scholtz(Director)inCaroline Popper(Director)in
Co-investorsTCP Venture CapitalPTX Capital
Integrated Biosciences is a biotech company developing small molecule therapeutics for age-related diseases, using optogenetics, chemistry, and AI to study aging biology.
AI & Machine LearningBiotechLongevityRedwood City, US
Felix Wong(Executive Officer, Director)inDaniel J. Anderson(Chief Scientific Officer)inThemasap Khan(Director)
BoardKeith Loebner(Director)
Co-investorsSutter Hill VenturesCivilization Ventures Management, LlcOverlap Holdings
Kallyope is a biotechnology company founded by neuroscientists that discovers and develops novel therapeutics targeting neural networks, with a lead candidate in pivotal studies for acute migraine treatment and metabolism programs approaching clinical studies.
BiotechHealthtechNew York City, US
Tom Maniatis(Founder)Nancy Thornberry(Executive Officer, Director)inKenneth Clark(Executive Officer)Charles Zuker(Founder)Richard Axel(Founder)
BoardTerry McGuire(Director)in
Co-investorsDns CapitalLux CapitalThe Column GroupPolaris PartnersTwo Sigma Ventures
Kodikaz develops Zip-Code, a non-viral cell-specific delivery platform for gene therapy applications, particularly focused on oncology and cancer treatments.
AI & Machine LearningBiotechMedical DevicesAtlanta, US
Anthony Johnson(Co-Founder & CEO)inDr. Leon Bernal-Mizrachi(Co-Founder, CSO)in
Co-investorsEpidarex CapitalGRA Venture
LetsGetChecked provides at-home healthcare including lab testing, virtual consultations, and prescription fulfillment, backed by its own manufacturing, logistics, and lab analysis infrastructure plus proprietary clinical and analytics software.
Digital HealthHealthtechMedical DevicesDublin, IE
Dr. Robert Mordkin(Chief Medical Officer)Oonagh O'Brien(Chief Executive Officer)inRonan Ryan(Chief Operations Officer)Mike Tesar(Chief Technology Officer)Michael Rummel(Chief Laboratory Officer)inPeter Foley(Founder)
Co-investorsFlucas VenturesK2 HealthVenturesOak HC/FTOptum VenturesTRANSFORMATION CAPITAL
Lightcast develops a single-cell functional analysis platform that uses droplet-based technology to profile cell function, biomolecule secretion, cell-cell interactions, and targeted cell killing at scale.
BiotechDeep TechHealthtech
Co-investors+ND CapitalLongwall Venture Partners LLPM VenturesOMX VenturesARCH Venture Partners
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsARCH Venture PartnersPerscitus LLP+ND CapitalIllumina InnovationM VenturesOMX Ventures
San Diego, US
Bob Kain(Executive Officer, Director)inDawn Barry(Executive Officer)inJoseph C. Beery(Executive Officer, Director)
Co-investorsARCH Venture PartnersBain Capital VenturesF-Prime Capital
Developer of microfluidic cell sorting technologies for the biotech industry.
BiotechHardwareMedical DevicesSan Diego, US
Jose Morachis(Executive Officer, Director)inNate Heintzman(Executive Officer, Director)inWilliam Alaynick(Executive Officer, Director)Chris Neary(CEO)in
BoardKenneth Hood(Director)
Co-investorsVertical Venture PartnersWarburg PincusAnzu PartnersFusionX VenturesHemisphere Ventures LLCPaladin Capital Group+1 more
NuCicer develops improved crop varieties through selective breeding, starting with high-protein chickpeas designed for better nutrition.
AgTechAI & Machine LearningFoodTechDavis, US
Kathryn Cook(Executive Officer, Director)inDouglas Cook(Executive Officer, Director)
BoardPaimun Amini(Director)inJerry Steiner(Director)inCarsten Boers(Director)in
Co-investorsBetter Ventures Central LlcBlue Horizon CorporationLever VCRhapsody Venture PartnersStray Dog CapitalTrellis Road I Fund AB+1 more
.png)
Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms.
AI & Machine LearningBiotechDeep Tech
Atray Dixit(Co-founder, CEO)inBill Grossman(Co-founder, Strategic Advisor)in
Co-investorsAdverb VenturesGaingelsTenmile
__Twitter.png)
Pattern Labs develops autonomous robotics and software systems for airport ground operations and dynamic logistics.
AI & Machine LearningLogistics & Supply ChainRoboticsErie, US
John Pratt(Founder)inMatt Fedick(Founder)in
Co-investorsE12 Venture Capital, LlcOrigin VenturesRPS VenturesService Provider CapitalAxon Partners GroupData Community Fund
Protillion Biosciences develops platform technology for antibody engineering and drug discovery.
AI & Machine LearningBiotechDeep TechCarlsbad, US
Curtis Layton(CEO/Co-Founder)inDavid Walt(Co-Founder)inWill Greenleaf(Co-Founder)inRobert Hollingsworth(Chief Scientific Officer)in
BoardSean Kendall(Director)inMalek Faham(Director)in
Co-investorsARCH Venture PartnersMerck Global Health Innovation FundMSD Global Health Innovation Fund
Santa Clara, US
Jekwan Ryu(Executive Officer, Director)Ronald M. Cook(Director)Eric Williams(Executive Officer)Tae Hoon Nahm(Director)
BoardTom Willis(Director, Executive Officer)in
Co-investorsWestern Technology Investment
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
BoardMike Dial(Director)in
Co-investorsHatteras Venture PartnersM VenturesMC Healthcare VenturesPappas CapitalSV Health InvestorsAbbVie+2 more
BiotechGoleta, US
Patrick Daugherty(Executive Officer, Director)Kristin Loomis(Director)Bill Welch(Director)inNick Naclerio(Director)inJohn Shon(Executive Officer)
Co-investorsIllumina Innovation
Serinus Biosciences uses AI and systems biology to design drug combinations that overcome cancer cells' resistance to existing treatments, targeting safer and more effective therapeutic options.
BiotechHealthtechNew York City, US
Adam Yaari(CEO)inMaxwell Sherman(CTO)in
Co-investorsMetaplanetPioneerSapir Venture PartnersVertex Ventures IsraelY CombinatorAlexandria+5 more
The company develops diagnostics and biological sample collection devices, including a rapid sickle-cell test, supporting infectious disease detection and genomic, metabolomic, and microbiome research.
BiotechHealthtechMedical DevicesCambridge, US
Rahul Dhanda(Executive Officer, Director)inJames Collins(Director)David Walt(Director)in
BoardIssi Rozen(Director)in
Co-investorsCatalio Capital Management, LPGaingelsCatalio Capital ManagementGood VenturesGV (Google Ventures)Northpond Ventures+1 more
SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way.
BiotechDeep TechDigital HealthHealthtechSouth San Francisco, US
Kenneth Greenberg(Co-Founder, President & CEO)in
Co-investorsVida VenturesLeaps by BayerARCH Venture PartnersFoothill VenturesMedical Excellence CapitalVivo Capital+8 more
BiotechWatertown, US
Robert S. Langer, Sc.D.(Director)Armon Sharei, Ph.D.(Executive Officer, Director)Armon Sharei(Executive Officer, Director)Amy W. Schulman(Executive Officer, Director)Kris Elverum(Executive Officer)Howard Bernstein(Executive Officer)
Co-investorsAlumni Ventures+ND CapitalGV (Google Ventures)InvusJDRF T1D FundQuark Venture Inc.+2 more
Co-investorsKurma PartnersPartech Ventures
Syntax Bio develops a discovery platform that accelerates stem cell-derived therapies by using its proprietary Cellgorithm technology to control and direct cell differentiation.
BiotechDeep TechMedical DevicesChicago, US
Ryan Clarke(Co-Founder, Chief Scientific Officer)inNiko Balanis, PhD(Co-Founder, Chief Technology Officer)inBrad Merrill, PhD(Co-Founder, Head of Innovation)Matt MacDougall, MD, PhD(Scientific Cofounder, Immunology Physician, Stanford University)inPatrick Shaddow(Executive Officer, Director)John Craighead, PhD(Chief Executive Officer)
Co-investorsAstellas Venture Management LLCDCVC (Data Collective)DCVC BioDraper AssociatesLong GamePortal Innovations+1 more
Tagomics develops multimodal technologies for precision medicine and next-generation diagnostics.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, GB
Dr Jack Kennefick(Co-founder, Director & Chief Executive Officer)Dr Robert Neely(Co-founder, Director & Chief Scientific Officer)
Co-investorsCalculus Capital Ltd.IQ CapitalCalculusIllumina InnovationInnovate UKMEIF Proof-of-Concept & Early Stage Fund+3 more
.jpeg){kind=logo}
BiotechCambridge, US
Shawn Marcell(Executive Officer, Director)Ben Linden(Executive Officer)inDavid Yu Zhang(Director)Peng Yin(Director)
BoardAdam Wiechhaus(Director)
Co-investorsNorthpond Ventures
Vizgen develops spatial profiling instruments and reagents for high-throughput analysis of gene expression and protein distribution in tissue samples.
AI & Machine LearningBiotechDeep TechMedical DevicesCambridge, US
George Emanuel(Scientific Cofounder, VP & Portfolio Owner, Instruments)inJiang He(Scientific Cofounder, VP & Portfolio Owner, Reagents & Scientific Affairs)inRobert Carson(Executive Officer, Director)Terry Lo(Director)inSeth Benson(Executive Officer)inSimona Levi(Executive Officer)in
Co-investorsARCH Venture PartnersM VenturesNorthpond VenturesNovalis LifeSciences
Walking Fish Therapeutics develops cell therapies aimed at restoring health and function in patients.
AI & Machine LearningBiotechHealthtechMedical DevicesSouth San Francisco, US
Lewis Williams(Co-founder & CEO)inRusty Williams(Founder)Antonin de Fougerolles(Director)Momo Wu(Director)Stella Xu(Director)Alexis Ji(Director)
Co-investorsFirst Spark Ventures, LlcPandect BioventuresNorthpond Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
DnascriptEncodedgenomicsPredicta
Exits · 1
1 IPOsCastle BiosciencesNASDAQ: CSTL
Portfolio news
latest coverage across their companies
SonoThera · fusfoundation.org · Jun 19, 2026
Arbor Biotechnologies · altss.com · Jun 3, 2026
Lightcast · finsmes.com · Apr 15, 2026
Vizgen · intelligence360.news · Feb 2, 2026
Frequently asked questions
- How many investments has Illumina Ventures made?
- Illumina Ventures has 58 tracked investments, 1 of which have exited, including 6 dated in the last 24 months.
- What stage does Illumina Ventures invest at?
- Illumina Ventures invests at the Seed, Series A stages.
- What sectors does Illumina Ventures focus on?
- Illumina Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is Illumina Ventures located?
- Illumina Ventures is headquartered in Foster City, US.
- Does Illumina Ventures lead rounds?
- Illumina Ventures typically participates in rounds rather than leading them.
- Who does Illumina Ventures co-invest with?
- Illumina Ventures most often shares deals with ARCH Venture Partners, Alumni Ventures, Catalio Capital Management, LP, among 119 tracked co-investors.
- What size deals does Illumina Ventures back?
- Across 14 deals with disclosed amounts, Illumina Ventures has joined rounds of $2.5M – $215M (median $23.5M).
Co-investors · 11
+ND Capital is a venture capital firm founded in 2002 focused on nanotechnology and deep science investments, backing companies in life sciences and physical sciences primarily in the US and Europe.
Kurma Partners is a European healthcare-focused investment firm that co-founds and finances biotech and healthcare companies, working closely with research centers to translate scientific discoveries into high-tech companies.
Catalio is a software platform that uses AI to automatically extract and document business logic from legacy and modern systems, creating living specifications that stay current as software evolves.
Casdin Capital is an investment firm focused on the life sciences, investing across healthcare, biotechnology, synthetic biology, and related technology.
Transformation Capital is an investment firm focused exclusively on the digital healthcare industry, backing founders working to transform and modernize health.
Paladin Capital Group invests in early stage and growth companies developing cyber, AI and deep technologies that address security and resilience needs for commercial and government customers.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
5AM Ventures is a life science venture capital firm founded in 2002 that funds and builds next-generation life sciences companies, focusing on biopharmaceuticals, drug delivery technologies, and life science instruments.
Qiming Venture Partners (启明创投) is a China-focused venture capital firm that invests in and supports early- and growth-stage technology and healthcare companies, providing capital, industry resources, and strategic guidance through milestones such as financing, IPOs, and M&A.
EQT Life Sciences (formerly LSP) is one of Europe's largest and most experienced life sciences investors, backing companies developing therapeutics, medical devices, diagnostics and healthtech globally.
Genoa Ventures is a venture capital firm investing at the convergence of biology and technology, backing early-stage companies poised to transform industries.
Firms observed investing alongside Illumina Ventures, from public investor directories. Shared companies are the overlap with Illumina Ventures's recorded portfolio.
Similar investors
Breyer Capital is an early-stage, high-conviction investment firm with a dedicated healthcare and life sciences practice backing founders rebuilding medicine at the intersection of science, data, care delivery, and economics.
Future Positive Capital is a venture firm that backs entrepreneurs building companies aimed at solving universal challenges at planetary scale across science and technology.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
LongeVC is a venture capital firm backing early-stage founders in biotech and longevity, aiming to bring breakthrough science and treatments to market.